Alphamab Oncology (HKG:9966) said the results of the two clinical studies of its JSKN003 support further clinical evaluation of the anti-tumor drug, according to a Sunday filing with the Hong Kong Stock Exchange.
The company's phase 1 study of JSKN003 in Australia showed "promising" efficacy in pretreated patients with platinum-resistant ovarian cancer, irrespective of HER2 expression.
Meanwhile, the phase 1 and phase 2 trials in China demonstrated a "promising" objective response rate with high HER2 expressing gastrointestinal tumor.
Shares closed 5% lower during Monday's trading.
Price (HKD): $2.35, Change: $-0.12, Percent Change: -4.86%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。